This article is more than 5 years old. Information may no longer be current.

Pfizer sales up during fourth quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NEW YORK — Revenues for Pfizer grew to $14.92 billion in the fourth quarter of 2004, up 7% from the same quarter in 2003, according to a company press release. The company attributed the increase in revenue to good performances from its cholesterol drugs and the weakening of the U.S. dollar. Full revenues for the year topped $52.52 billion, an increase of 17% when compared with 2003.

Net income for the full year 2004 was $11.36 billion, the company said in the release. Fourth-quarter human health revenue was up 6% to $13.1 billion from the same quarter in the previous year, the company said.

Sales of Xalatan (latanoprost) and Xalacom (latanoprost and timolol maleate) increased 23% during the quarter.

“Full year Xalatan sales surpassed $1 billion in 2004, and [the drug] has displaced beta blockers as the accepted gold standard in IOP-lowering agents,” the company said in its press release.

Other ophthalmic highlights for the quarter included the approval in December of the age-related macular degeneration drug Macugen (pegaptanib sodium injection), which Pfizer co-promotes with Eyetech Pharmaceuticals.